Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Income towards Parent Company: 2010-2025

Historic Income towards Parent Company for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $846,000.

  • Anika Therapeutics' Income towards Parent Company rose 103.01% to $846,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.8 million, marking a year-over-year decrease of 56.50%. This contributed to the annual value of -$47.6 million for FY2024, which is 39.97% up from last year.
  • Latest data reveals that Anika Therapeutics reported Income towards Parent Company of $846,000 as of Q3 2025, which was up 24.96% from $677,000 recorded in Q2 2025.
  • Anika Therapeutics' 5-year Income towards Parent Company high stood at $16.2 million for Q4 2023, and its period low was -$28.1 million during Q3 2024.
  • For the 3-year period, Anika Therapeutics' Income towards Parent Company averaged around -$4.6 million, with its median value being -$2.6 million (2024).
  • Data for Anika Therapeutics' Income towards Parent Company shows a peak YoY increase of 411.38% (in 2022) and a maximum YoY decrease of 853.99% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Income towards Parent Company stood at -$3.2 million in 2021, then soared by 411.38% to $10.1 million in 2022, then surged by 60.71% to $16.2 million in 2023, then slumped by 219.74% to -$19.4 million in 2024, then skyrocketed by 103.01% to $846,000 in 2025.
  • Its last three reported values are $846,000 in Q3 2025, $677,000 for Q2 2025, and -$915,000 during Q1 2025.